Insider · CIK 0001532793
Gary S. Stetz
Files at HEPA (Hepion Pharmaceuticals, Inc.), CNTN (Tharimmune, Inc.). First filing Apr 27, 2026, latest Aug 12, 2026.
In brief
Gary S. Stetz files SEC Form 4 as director and CEO at HEPA (Hepion Pharmaceuticals, Inc.), and also at CNTN (Tharimmune, Inc.). Since Apr 27, 2026, Gary S. Stetz has reported 2 open-market buys worth $150k and 1 open-market sell worth $344k, the latest filed on Aug 12, 2026.
A track record needs three past buys with six months of prices behind them; Gary S. Stetz has 0, so none is measured yet.
The newest scored trade: bought $100k of HEPA on Aug 3, 2026, filed Aug 12, 2026, scored 64 (notable). In the last 12 months: 2 buys worth $150k and 1 sell worth $344k.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
HEPA: Hepion Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
CNTN: Tharimmune, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 64Notable | Hepion Pharmaceuticals, Inc. | $100k 2,000,000 shares | +160% | +106% from low-24% from high | |
| 40Moderate | CNTNsell Tharimmune, Inc. | $344k 100,351 shares | -43% | +201% from low-54% from high | |
| 63Notable | Hepion Pharmaceuticals, Inc. | $50k 1,250,000 shares | - | +14% from low-90% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | HEPA Hepion Pharmaceuticals, Inc. | AGrant or award Stock Optionsderivative | +1,345,500 | $0.00 | $0 | 1,345,500 | Aug 21, 2026 |
| Aug 3, 2026 | HEPA Hepion Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +2,000,000 | $0.05 | $100k | 3,250,000 | Aug 12, 2026 |
| Aug 3, 2026 | HEPA Hepion Pharmaceuticals, Inc. | POpen-market purchase Warrantsderivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Aug 12, 2026 |
| May 22, 2026 | CNTN Tharimmune, Inc. | SOpen-market sale Common Stock | -10,000 | $3.45 | $35k | 224,526 | May 27, 2026 |
| May 22, 2026 | CNTN Tharimmune, Inc. | SOpen-market sale Common Stock | -10,000 | $3.45 | $35k | 214,526 | May 27, 2026 |
| May 22, 2026 | CNTN Tharimmune, Inc. | SOpen-market sale Common Stock | -15,000 | $3.40 | $51k | 199,526 | May 27, 2026 |
| May 22, 2026 | CNTN Tharimmune, Inc. | SOpen-market sale Common Stock | -15,000 | $3.41 | $51k | 184,526 | May 27, 2026 |
| May 22, 2026 | CNTN Tharimmune, Inc. | SOpen-market sale Common Stock | -15,000 | $3.41 | $51k | 169,526 | May 27, 2026 |
| May 22, 2026 | CNTN Tharimmune, Inc. | SOpen-market sale Common Stock | -10,000 | $3.40 | $34k | 159,526 | May 27, 2026 |
| May 22, 2026 | CNTN Tharimmune, Inc. | SOpen-market sale Common Stock | -12,851 | $3.44 | $44k | 146,675 | May 27, 2026 |
| May 26, 2026 | CNTN Tharimmune, Inc. | SOpen-market sale Common Stock | -12,500 | $3.47 | $43k | 134,175 | May 27, 2026 |
| Apr 21, 2026 | HEPA Hepion Pharmaceuticals, Inc. | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: See Footnote | +1,250,000 | $0.04 | $50k | 1,250,000 | Apr 27, 2026 |
| Nov 3, 2025 | CNTN Tharimmune, Inc. | AGrant or award Stock Optionderivative | +32,500 | $0.00 | $0 | 82,500 | Nov 5, 2025 |
Questions about Gary S. Stetz
Answered from the filings on this page, as of the latest one.
Is Gary S. Stetz buying or selling?
In the last 12 months Gary S. Stetz reported 2 open-market buys worth $150k and 1 open-market sell worth $344k on SEC Form 4; the latest was bought $100k of HEPA on Aug 3, 2026. Grants, option exercises and tax withholding are not counted.
How did Gary S. Stetz's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Gary S. Stetz has 0.
Where does Gary S. Stetz file Form 4?
Gary S. Stetz has filed Form 4 at HEPA (Hepion Pharmaceuticals, Inc.) as Interim CEO; CNTN (Tharimmune, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.